NeoGenomics (MEX:NEO) Research & Development: MXN684 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NEO NeoGenomics Inc MEX:NEO
74 GF Score
Price MXN176.40
GF Value MXN177.40
! 6 Warning Signs
View Full Analysis

What is NeoGenomics Research & Development?

NeoGenomics MEX:NEO 74 Research & Development is MXN684 Mil as of Jun. 2026. GuruFocus rates MEX:NEO with a GF Score™ of 74/100 and a GF Value™ of MXN177.40. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. NeoGenomics's Research & Development for the three months ended in Jun. 2026 was MXN188 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was MXN684 Mil.

NeoGenomics  (MEX:NEO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

NeoGenomics Research & Development Related Terms

NeoGenomics Research & Development Historical Data

* Premium members only.

The historical data trend for NeoGenomics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoGenomics Research & Development Chart

NeoGenomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 448.70 591.24 463.55 649.84 667.60

NeoGenomics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 169.90 159.48 165.27 171.92 187.77
MEX:NEO
74GF Score
NeoGenomics Inc MEX:NEO
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeoGenomics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN684 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of MXN684 Mil mean?
NeoGenomics (MEX:NEO) has a Research & Development of MXN684 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on NeoGenomics and its competitors.
Is NeoGenomics' Research & Development too high?
NeoGenomics' current Research & Development is MXN684 Mil. Overall, NeoGenomics has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' Research & Development compare to WGS and CDNA?
NeoGenomics' Research & Development of MXN684 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on NeoGenomics and its competitors. NeoGenomics's current Research & Development is MXN684 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
NeoGenomics (MEX:NEO) has a current Research & Development of MXN684 Mil. The stock's GF Value™ is MXN177.40, compared to a current price of MXN176.40 — trading 0.6% below its estimated fair value. The current Research & Development is MXN684 Mil. NeoGenomics' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For NeoGenomics (MEX:NEO), the current Research & Development is MXN684 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeoGenomics (MEX:NEO) Overvalued in 2026?

Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued. The current stock price of MXN176.40 is trading 0.6% below its estimated GF Value™ of MXN177.40.

Key valuation signals for MEX:NEO:

  • Research & Development: MXN684 Mil
  • GF Value™: MXN177.40 vs. price of MXN176.40 (0.6% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the MEX:NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeoGenomics Business Description

Other Exchanges NEO:USANG9:Germany
Address 9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
74GF Score

Get the complete analysis for MEX:NEO

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN176.40
Price
MXN177.40
GF Value